Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, Affymetrix

Premium

GE Healthcare, formerly Amersham Biosciences, of Uppsala, Sweden, has received US Patent No. 6,986,992, "P450 single nucleotide polymorphism biochip analysis." The patent claims methods and compositions for determining single nucleotide polymorphisms in P450 genes. According to the patent, the self extension of interrogation probes is prevented by using non self-extension probes to improve the specificity of P450 SNP detection in target samples with minimal false positive results. In addition, the patent claims a collection of P450 SNP probes on one assay, primer sequences for specific amplification of each of the seven P450 genes and amplicon control probes to evaluate whether the intended p450 gene targets were amplified successfully. The invention also describes a variety of array platforms for performing the assays of the invention, including GE Healthcare's CodeLink, Osmetech's eSensor system, and multiplex arrays with cartridges.


Affymetrix of Santa Clara, Calif., has received US Patent No. 6,988,040, "System, method, and computer software for genotyping analysis and identification of allelic imbalance." The patent claims methods, systems and computer software products for determining the genotype of a sample using a plurality of probes. In one preferred embodiment of the invention, a tentative genotype call is made based upon the relative allele signals. Pattern recognition is then used to validate the tentative call, according to the patent.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.